Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine

Inclusion Criteria: * Patients that give their informed consent before the procedures of study * Thrombocytopenia before intervention (\<100 x10\^9 /L) * Patients of either biological sex older than 15 years old * Patients with previous diagnosis of primary immune thrombocytopenia that not reach complete remission after treatment (steroid based) or that have a relapse * If the patient is taking steroid based treatment, the dose need to be stable before intervention. Exclusion Criteria: * Patients with secondary immune thrombocytopenia * Pregnant patients * Patients with hypersensitivity to study treatments * Patients that are taking anticoagulant medication or any drug that have an effect on platelet count * Hepatic alteration consisting in serum levels of Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 3 times above superior laboratory reference limit. * Elevation of serum levels of Creatinine or bilirubins above 1.5 mg/dl * Any cancer diagnosis * Coronary heart disease, congestive heart failure, uncontrolled hypertension or arrhythmias. * Previous autoimmune disease diagnosis including: systemic lupus erythematosus, rheumatoid arthritis or systemic sclerosis.